Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Haematological malignancies

4964 - Does the omission of vincristine affect outcome and survival in patients with diffuse large B-cell lymphoma?

Date

11 Sep 2017

Session

Haematological malignancies

Presenters

Charlott Mörth

Citation

Annals of Oncology (2017) 28 (suppl_5): v355-v371. 10.1093/annonc/mdx373

Authors

C. Mörth1, A. Valachis1, A. Abu Sabaa2, G. Hedström2, M. Flogegård2, G. Enblad2

Author affiliations

  • 1 Uppsala University, Centre for Clinical research Sörmland, 63188 - Eskilstuna/SE
  • 2 Uppsala University, Department of Immunology, Genetics and Pathology, 75185 - Uppsala/SE
More

Resources

Abstract 4964

Background

The current standard treatment for diffuse large B-cell lymphoma (DLBCL) is Rituximab-CHOP (cyclophosphamide (CPM), doxorubicin(DXR), vincristine(VCR), prednisolone). It is well known that VCR causes peripheral neuropathy and is often dose-reduced or omitted from the treatment. Whether the omission of VCR from 1 or more cycles of therapy could jeopardize the survival of patients with DLBCL has not yet been adequately addressed. Our study aimed to investigate any differences in progression free (PFS) and overall (OS) survival in R-CHOP treated patients with DLBCL between those with omission of VCR or not.

Methods

In this Swedish multi-institutional, retrospective, cohort study we included all adult patients diagnosed with and primarily treated for DLBCL or subgroups of high-grade malignant B-cell lymphoma with either R-CHOP/CHOEP (CHOP plus Etoposide) or mini-CHOP (dose-reduced), between 2000-2013. All information on patients’ characteristics, treatment outcome, and survival was extracted from the in-hospital computer based systems. Any clinical variables significantly associated with PFS or OS in univariate analysis by the log-rank test were considered for entry into a multivariate Cox proportional hazard regression model. Omission of VCR was included in all models as an independent variable of interest. All statistical analyses were performed with IBM SPSS statistics version 22.

Results

In total 541 patients were included in the study cohort. In 95 (17.6%) patients, VCR was omitted due to toxicity. The omission was more often decided during the last 3 cycles of chemotherapy (86 patients, 90.5%). Univariate analysis revealed 9 potential prognostic factors associated with PFS and 10 with OS. Omission of VCR was not associated with either PFS or OS in both univariate and multivariate analyses (HR for PFS: 1.21, 95% Confidence Interval (CI) 0.76-1.95; HR for OS; 1.12, 95% CI 0.75-1.69). For PFS only advanced stage at diagnosis was found to be significantly associated with worse outcome (p = 0.047). In respect of OS kidney/adrenal involvement (p = 0.014), Doxorubicin –RelativeDoseIntensity 22.04 (1.01-4.00)0.0471.59 (0.88-2.88)0.127IPI > 21.33 (0,70-2.50)0.3851.14 (0.60-2.17)0.686LDH > ULN1.09 (0.63-1.89)0.7781.03 (0.63-1.69)0.893Bulkyb1.30 (0.81-2.10)0.2831.58 (1.03-2.42)0.037Oncovin omissionc1.21 (0,76-1.95)0.4211.12 (0.75-1.69)0.571Extranodald >11.02 (0.59-1.78)0.932Not includedKidney/Adrenale1.72 (0.78-3.85)0.1712.45 (1.20-4.98)0.014BMI ≥ 250.89 (0.58-1.37)0.5910.98 (0.67-1.43)0.904DoxoRDI ≤ 70%1.88 (0.97-3.67)0.0632.04 (1.15-3.57)0.014

Conclusions

Omission of VCR does not affect either PFS or OS in patients with DLBCL treated with R-CHOP/CHOEP. As a result, clinicians can safely decide to omit VCR in case of severe neurotoxicity due to VCR. Considering the association of bulky disease and kidney/adrenal manifestation of lymphoma on survival, further studies should focus on whether the treatment options for these subgroups need to be individualized. Finally, clinicians should be aware of the importance of giving adequate dose of DXR during treatment given the growing body of evidence on the role of dose intensity on survival.

Clinical trial identification

Legal entity responsible for the study

Charlott Mörth

Funding

Centre for Clinical research Sörmland, Uppsala university

Disclosure

All authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.